Respondents broadly supported clearer guidance on how evidence on health inequalities should be presented and how impacts are ...

For well over a decade, scientists, health leaders, and global organisations have sounded the alarm on antimicrobial ...

Connecting 80+ EHS experts in pharma and biopharma on the West coast, this year's meeting will address the challenges of ...

Despite a certain amount of upheaval at the FDA, the agency has continued to keep up with its scheduled approvals and ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

The deal for CARGO, which remains relatively well funded despite its troubles, comes with a contingent value right (CVR) that ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new 10-year plan for the NHS ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

Whether stemming from early childhood adversity, combat exposure, or interpersonal abuse, trauma leaves long-term imprints on ...

Improving efficiencies and uncomplicating processes are critical to the future success of NHS Trusts across the country. The ...